O	0	8	Impaired	Impaired	JJ	B-NP
O	9	18	apoptosis	apoptosis	NN	I-NP
O	19	21	of	of	IN	B-PP
B-Cell	22	31	pulmonary	pulmonary	JJ	B-NP
I-Cell	32	43	endothelial	endothelial	JJ	I-NP
I-Cell	44	49	cells	cell	NNS	I-NP
O	50	52	is	be	VBZ	B-VP
O	53	63	associated	associate	VBN	I-VP
O	64	68	with	with	IN	B-PP
B-Tissue	69	76	intimal	intimal	JJ	B-NP
O	77	90	proliferation	proliferation	NN	I-NP
O	91	94	and	and	CC	I-NP
O	95	110	irreversibility	irreversibility	NN	I-NP
O	111	113	of	of	IN	B-PP
B-Organ	114	123	pulmonary	pulmonary	JJ	B-NP
O	124	136	hypertension	hypertension	NN	I-NP
O	137	139	in	in	IN	B-PP
O	140	150	congenital	congenital	JJ	B-NP
B-Organ	151	156	heart	heart	NN	I-NP
O	157	164	disease	disease	NN	I-NP
O	164	165	.	.	.	O

O	166	176	OBJECTIVES	OBJECTIVES	NNS	B-NP
O	176	177	:	:	:	O
O	178	182	This	This	DT	B-NP
O	183	188	study	study	NN	I-NP
O	189	195	sought	seek	VBD	B-VP
O	196	198	to	to	TO	I-VP
O	199	205	assess	assess	VB	I-VP
O	206	209	the	the	DT	B-NP
B-Cell	210	218	cellular	cellular	JJ	I-NP
O	219	222	and	and	CC	I-NP
O	223	233	histologic	histologic	JJ	I-NP
O	234	239	basis	basis	NN	I-NP
O	240	242	of	of	IN	B-PP
O	243	255	irreversible	irreversible	JJ	B-NP
B-Organ	256	265	pulmonary	pulmonary	JJ	I-NP
O	266	278	hypertension	hypertension	NN	I-NP
O	279	280	(	(	(	O
O	280	283	PHT	PHT	NN	B-NP
O	283	284	)	)	)	O
O	285	287	in	in	IN	B-PP
O	288	291	the	the	DT	B-NP
O	292	300	clinical	clinical	JJ	I-NP
O	301	308	setting	setting	NN	I-NP
O	309	311	of	of	IN	B-PP
O	312	322	congenital	congenital	JJ	B-NP
B-Organ	323	328	heart	heart	NN	I-NP
O	329	336	disease	disease	NN	I-NP
O	337	338	(	(	(	O
O	338	341	CHD	CHD	NN	B-NP
O	341	342	)	)	)	O
O	342	343	.	.	.	O

O	344	354	BACKGROUND	BACKGROUND	NN	B-NP
O	354	355	:	:	:	O
O	356	364	Although	Although	IN	B-SBAR
O	365	369	many	many	JJ	B-NP
O	370	378	children	child	NNS	I-NP
O	379	383	with	with	IN	B-PP
O	384	387	CHD	CHD	NN	B-NP
O	388	395	develop	develop	VBP	B-VP
B-Multi-tissue_structure	396	405	pulmonary	pulmonary	JJ	B-NP
I-Multi-tissue_structure	406	414	vascular	vascular	JJ	I-NP
O	415	422	disease	disease	NN	I-NP
O	422	423	,	,	,	O
O	424	426	it	it	PRP	B-NP
O	427	429	is	be	VBZ	B-VP
O	430	437	unclear	unclear	JJ	B-ADJP
O	438	441	why	why	WRB	B-ADVP
O	442	446	this	this	DT	B-NP
O	447	459	complication	complication	NN	I-NP
O	460	462	is	be	VBZ	B-VP
O	463	473	reversible	reversible	JJ	B-ADJP
O	474	479	after	after	IN	B-SBAR
O	480	488	complete	complete	JJ	B-NP
O	489	495	repair	repair	NN	I-NP
O	496	498	in	in	IN	B-PP
O	499	503	some	some	DT	B-NP
O	504	509	cases	case	NNS	I-NP
O	510	513	but	but	CC	O
O	514	526	irreversible	irreversible	JJ	B-ADJP
O	527	529	in	in	IN	B-PP
O	530	536	others	other	NNS	B-NP
O	536	537	.	.	.	O

O	538	545	Because	Because	IN	B-SBAR
O	546	553	failure	failure	NN	B-NP
O	554	556	of	of	IN	B-PP
B-Cell	557	568	endothelial	endothelial	JJ	B-NP
I-Cell	569	573	cell	cell	NN	I-NP
O	574	583	apoptosis	apoptosis	NN	I-NP
O	584	589	might	might	MD	B-VP
O	590	594	lead	lead	VB	I-VP
O	595	597	to	to	TO	B-PP
B-Tissue	598	605	intimal	intimal	JJ	B-NP
O	606	619	proliferation	proliferation	NN	I-NP
O	620	623	and	and	CC	I-NP
O	624	628	lack	lack	NN	I-NP
O	629	631	of	of	IN	B-PP
O	632	645	reversibility	reversibility	NN	B-NP
O	646	648	of	of	IN	B-PP
O	649	652	PHT	PHT	NN	B-NP
O	652	653	,	,	,	O
O	654	656	we	we	PRP	B-NP
O	657	669	investigated	investigate	VBD	B-VP
O	670	674	this	this	DT	B-NP
O	675	678	and	and	CC	O
O	679	684	other	other	JJ	B-NP
O	685	688	key	key	JJ	I-NP
O	689	696	markers	marker	NNS	I-NP
O	697	699	of	of	IN	B-PP
O	700	712	vasoactivity	vasoactivity	NN	B-NP
O	713	716	and	and	CC	I-NP
O	717	729	angiogenesis	angiogenesis	NN	I-NP
O	730	732	in	in	IN	B-PP
O	733	741	subjects	subject	NNS	B-NP
O	742	746	with	with	IN	B-PP
O	747	750	PHT	PHT	NN	B-NP
O	751	754	and	and	CC	I-NP
O	755	758	CHD	CHD	NN	I-NP
O	758	759	.	.	.	O

O	760	767	METHODS	METHODS	NNS	B-NP
O	767	768	:	:	:	O
O	769	771	We	We	PRP	B-NP
O	772	780	assessed	assess	VBD	B-VP
O	781	794	antiapoptotic	antiapoptotic	JJ	B-NP
O	795	798	and	and	CC	I-NP
O	799	811	proapoptotic	proapoptotic	JJ	I-NP
O	812	819	markers	marker	NNS	I-NP
O	820	822	in	in	IN	B-PP
B-Cell	823	831	vascular	vascular	JJ	B-NP
O	832	835	and	and	CC	I-NP
B-Cell	836	848	perivascular	perivascular	JJ	I-NP
I-Cell	849	854	cells	cell	NNS	I-NP
O	855	857	in	in	IN	B-PP
B-Multi-tissue_structure	858	862	lung	lung	NN	B-NP
I-Multi-tissue_structure	863	869	biopsy	biopsy	NN	I-NP
I-Multi-tissue_structure	870	877	samples	sample	NNS	I-NP
O	878	882	from	from	IN	B-PP
O	883	885	18	18	CD	B-NP
O	886	894	patients	patient	NNS	I-NP
O	895	899	with	with	IN	B-PP
O	900	903	CHD	CHD	NN	B-NP
O	903	904	,	,	,	O
O	905	906	7	7	CD	B-NP
O	907	911	with	with	IN	B-PP
O	912	922	reversible	reversible	JJ	B-NP
O	923	926	and	and	CC	I-NP
O	927	929	11	11	CD	I-NP
O	930	934	with	with	IN	B-PP
O	935	947	irreversible	irreversible	JJ	B-NP
O	948	951	PHT	PHT	NN	I-NP
O	951	952	,	,	,	O
O	953	956	and	and	CC	O
O	957	958	6	6	CD	B-NP
O	959	966	control	control	NN	I-NP
O	967	975	patients	patient	NNS	I-NP
O	975	976	.	.	.	O

O	977	991	Immunostaining	Immunostaining	NN	B-NP
O	992	995	for	for	IN	B-PP
O	996	1007	endothelial	endothelial	JJ	B-NP
O	1008	1014	nitric	nitric	JJ	I-NP
O	1015	1020	oxide	oxide	NN	I-NP
O	1021	1029	synthase	synthase	NN	I-NP
O	1029	1030	,	,	,	O
O	1031	1039	vascular	vascular	JJ	B-NP
O	1040	1051	endothelial	endothelial	JJ	I-NP
O	1052	1058	growth	growth	NN	I-NP
O	1059	1065	factor	factor	NN	I-NP
O	1065	1066	,	,	,	O
O	1067	1070	and	and	CC	O
O	1071	1075	CD34	CD34	NN	B-NP
O	1076	1077	(	(	(	O
O	1077	1084	markers	marker	NNS	B-NP
O	1085	1087	of	of	IN	B-PP
O	1088	1100	vasoactivity	vasoactivity	NN	B-NP
O	1101	1104	and	and	CC	I-NP
O	1105	1120	neoangiogenesis	neoangiogenesis	NN	I-NP
O	1120	1121	)	)	)	O
O	1122	1125	was	be	VBD	B-VP
O	1126	1130	also	also	RB	I-VP
O	1131	1140	performed	perform	VBN	I-VP
O	1140	1141	.	.	.	O

O	1142	1149	RESULTS	RESULTS	NNS	B-NP
O	1149	1150	:	:	:	O
O	1151	1154	The	The	DT	B-NP
O	1155	1168	antiapoptotic	antiapoptotic	JJ	I-NP
O	1169	1176	protein	protein	NN	I-NP
O	1177	1180	Bcl	Bcl	NN	I-NP
O	1180	1181	-	-	HYPH	O
O	1181	1182	2	2	CD	B-NP
O	1183	1186	was	be	VBD	B-VP
O	1187	1193	highly	highly	RB	I-VP
O	1194	1203	expressed	express	VBN	I-VP
O	1204	1206	by	by	IN	B-PP
B-Cell	1207	1216	pulmonary	pulmonary	JJ	B-NP
I-Cell	1217	1228	endothelial	endothelial	JJ	I-NP
I-Cell	1229	1234	cells	cell	NNS	I-NP
O	1235	1237	in	in	IN	B-PP
O	1238	1241	all	all	DT	B-NP
O	1242	1247	cases	case	NNS	I-NP
O	1248	1250	of	of	IN	B-PP
O	1251	1263	irreversible	irreversible	JJ	B-NP
O	1264	1267	PHT	PHT	NN	I-NP
O	1268	1271	but	but	CC	B-PP
O	1272	1274	in	in	IN	B-PP
O	1275	1277	no	no	DT	B-NP
O	1278	1283	cases	case	NNS	I-NP
O	1284	1286	of	of	IN	B-PP
O	1287	1297	reversible	reversible	JJ	B-NP
O	1298	1301	PHT	PHT	NN	I-NP
O	1301	1302	,	,	,	B-PP
O	1303	1306	nor	nor	CC	I-PP
O	1307	1309	in	in	IN	B-PP
O	1310	1317	control	control	NN	B-NP
O	1318	1326	patients	patient	NNS	I-NP
O	1327	1328	(	(	(	O
O	1328	1329	p	p	NN	B-NP
O	1331	1335	less	less	JJR	B-NP
O	1336	1340	than	than	IN	I-NP
O	1342	1343	0	0	CD	I-NP
O	1343	1344	.	.	.	I-NP
O	1344	1347	001	001	CD	I-NP
O	1347	1348	)	)	)	O
O	1348	1349	.	.	.	O

B-Tissue	1350	1357	Intimal	Intimal	JJ	B-NP
O	1358	1371	proliferation	proliferation	NN	I-NP
O	1372	1375	was	be	VBD	B-VP
O	1376	1383	present	present	JJ	B-ADJP
O	1384	1386	in	in	IN	B-PP
O	1387	1389	10	10	CD	B-NP
O	1390	1392	of	of	IN	B-PP
O	1393	1395	11	11	CD	B-NP
O	1396	1408	irreversible	irreversible	JJ	I-NP
O	1409	1412	PHT	PHT	NN	I-NP
O	1413	1418	cases	case	NNS	I-NP
O	1418	1419	,	,	,	O
O	1420	1423	but	but	CC	O
O	1424	1429	never	never	RB	B-VP
O	1430	1438	observed	observe	VBN	I-VP
O	1439	1441	in	in	IN	B-PP
O	1442	1452	reversible	reversible	JJ	B-NP
O	1453	1456	PHT	PHT	NN	I-NP
O	1457	1458	(	(	(	O
O	1458	1459	p	p	NN	B-NP
O	1461	1465	less	less	JJR	B-NP
O	1466	1470	than	than	IN	I-NP
O	1472	1473	0	0	CD	I-NP
O	1473	1474	.	.	.	I-NP
O	1474	1477	001	001	CD	I-NP
O	1477	1478	)	)	)	O
O	1478	1479	.	.	.	O

O	1480	1489	Similarly	Similarly	RB	B-ADVP
O	1489	1490	,	,	,	O
B-Cell	1491	1503	perivascular	perivascular	JJ	B-NP
I-Cell	1504	1516	inflammatory	inflammatory	JJ	I-NP
I-Cell	1517	1518	T	T	NN	I-NP
I-Cell	1518	1519	-	-	HYPH	I-NP
I-Cell	1519	1524	cells	cell	NNS	I-NP
O	1525	1534	expressed	express	VBD	B-VP
O	1535	1539	more	more	RBR	B-NP
O	1540	1553	antiapoptotic	antiapoptotic	JJ	I-NP
O	1554	1562	proteins	protein	NNS	I-NP
O	1563	1565	in	in	IN	B-PP
O	1566	1578	irreversible	irreversible	JJ	B-NP
O	1579	1582	PHT	PHT	NN	I-NP
O	1583	1584	(	(	(	O
O	1584	1585	p	p	NN	B-NP
O	1587	1591	less	less	JJR	B-NP
O	1592	1596	than	than	IN	I-NP
O	1598	1599	0	0	CD	I-NP
O	1599	1600	.	.	.	I-NP
O	1600	1602	01	01	CD	I-NP
O	1602	1603	)	)	)	O
O	1603	1604	.	.	.	O

O	1605	1617	Irreversible	Irreversible	JJ	B-NP
O	1618	1621	PHT	PHT	NN	I-NP
O	1622	1627	cases	case	NNS	I-NP
O	1628	1632	were	be	VBD	B-VP
O	1633	1637	also	also	RB	B-ADVP
O	1638	1642	more	more	RBR	B-ADJP
O	1643	1649	likely	likely	JJ	I-ADJP
O	1650	1652	to	to	TO	B-VP
O	1653	1657	show	show	VB	I-VP
O	1658	1670	compensatory	compensatory	JJ	B-NP
O	1671	1683	upregulation	upregulation	NN	I-NP
O	1684	1686	of	of	IN	B-PP
O	1687	1695	vascular	vascular	JJ	B-NP
O	1696	1707	endothelial	endothelial	JJ	I-NP
O	1708	1714	growth	growth	NN	I-NP
O	1715	1721	factor	factor	NN	I-NP
O	1722	1725	and	and	CC	O
O	1726	1729	new	new	JJ	B-NP
O	1730	1735	small	small	JJ	I-NP
B-Multi-tissue_structure	1736	1742	vessel	vessel	NN	I-NP
O	1743	1752	formation	formation	NN	I-NP
O	1753	1755	at	at	IN	B-PP
O	1756	1759	the	the	DT	B-NP
B-Multi-tissue_structure	1760	1765	sites	site	NNS	I-NP
O	1766	1768	of	of	IN	B-PP
O	1769	1775	native	native	JJ	B-NP
B-Multi-tissue_structure	1776	1782	vessel	vessel	NN	I-NP
O	1783	1791	stenosis	stenosis	NN	I-NP
O	1792	1794	or	or	CC	O
O	1795	1804	occlusion	occlusion	NN	B-NP
O	1805	1806	(	(	(	O
O	1806	1807	p	p	NN	B-NP
O	1809	1813	less	less	JJR	B-NP
O	1814	1818	than	than	IN	I-NP
O	1820	1821	0	0	CD	I-NP
O	1821	1822	.	.	.	I-NP
O	1822	1825	001	001	CD	I-NP
O	1825	1826	)	)	)	O
O	1826	1827	.	.	.	O

O	1828	1839	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1839	1840	:	:	:	O
O	1841	1853	Irreversible	Irreversible	JJ	B-NP
O	1854	1857	PHT	PHT	NN	I-NP
O	1858	1860	is	be	VBZ	B-VP
O	1861	1869	strongly	strongly	RB	I-VP
O	1870	1880	associated	associate	VBN	I-VP
O	1881	1885	with	with	IN	B-PP
O	1886	1894	impaired	impaired	JJ	B-NP
B-Cell	1895	1906	endothelial	endothelial	JJ	I-NP
I-Cell	1907	1911	cell	cell	NN	I-NP
O	1912	1921	apoptosis	apoptosis	NN	I-NP
O	1922	1925	and	and	CC	O
O	1926	1939	antiapoptotic	antiapoptotic	JJ	B-NP
O	1940	1949	signaling	signaling	NN	I-NP
O	1950	1954	from	from	IN	B-PP
B-Cell	1955	1967	perivascular	perivascular	JJ	B-NP
I-Cell	1968	1980	inflammatory	inflammatory	JJ	I-NP
I-Cell	1981	1986	cells	cell	NNS	I-NP
O	1986	1987	.	.	.	O

O	1988	1993	These	These	DT	B-NP
O	1994	2001	changes	change	NNS	I-NP
O	2002	2005	are	be	VBP	B-VP
O	2006	2016	associated	associate	VBN	I-VP
O	2017	2021	with	with	IN	B-PP
B-Tissue	2022	2029	intimal	intimal	JJ	B-NP
O	2030	2043	proliferation	proliferation	NN	I-NP
O	2044	2047	and	and	CC	O
B-Multi-tissue_structure	2048	2054	vessel	vessel	NN	B-NP
O	2055	2064	narrowing	narrowing	NN	I-NP
O	2064	2065	,	,	,	O
O	2066	2069	and	and	CC	O
O	2070	2077	thereby	thereby	RB	B-VP
O	2078	2081	may	may	MD	I-VP
O	2082	2092	contribute	contribute	VB	I-VP
O	2093	2095	to	to	TO	B-PP
O	2096	2104	clinical	clinical	JJ	B-NP
O	2105	2113	outcomes	outcome	NNS	I-NP
O	2114	2124	associated	associate	VBN	B-VP
O	2125	2129	with	with	IN	B-PP
B-Organ	2130	2139	pulmonary	pulmonary	JJ	B-NP
O	2140	2152	hypertension	hypertension	NN	I-NP
O	2152	2153	.	.	.	O

